Results 51 to 60 of about 23,157 (220)

Patterns of daily oral HIV PrEP adherence among people who inject drugs in Ukraine: an analysis of biomarkers

Journal of the International AIDS Society
Introduction Daily oral HIV pre‐exposure prophylaxis (PrEP) with tenofovir/emtricitabine (TDF/FTC) is recommended for people who inject drugs (PWID) but coverage is low.
Olga Morozova, Marina Kornilova, Olena Makarenko, Svitlana Antoniak, Mariia Liulchuk, Olga Varetska, Kostyantyn Dumchev   +6 more
doaj   +1 more source

Emtricitabine-induced pure red cell aplasia

Southern African Journal of HIV Medicine, 2019
Introduction: Anemia is common in HIV. Parvo B19 infection is a well-recognised cause of red cell aplasia. Other causes of persistent pure red cell aplasia (PRCA) include anti-retroviral drugs such as zidovudine and lamivudine. We describe a case of PRCA
Nithendra Manickchund, Camille du Plessis, Melanie-Anne A. John, Thandekile C. Manzini, Bernadett I. Gosnell, Richard J. Lessells, Yunus S. Moosa   +6 more
doaj   +1 more source

HIV drug resistance and treatment success in the Republic of Congo: Implications for optimized treatment

HIV Medicine, EarlyView.
Abstract Objectives Increasing rates of HIV‐1 drug resistance (HIVDR) threaten the effectiveness of antiretroviral therapy (ART) programmes in sub‐Saharan Africa, particularly among children, adolescents and young adults, who face limited treatment options.
Dominic Rauschning, Arcy Marcelin Elenga Ike, Johanna Holterhoff, Amira Stockinger, Darrel Ornelle Elion Assiana, Claujens Chastel Mfoutou Mapanguy, Freisnel Hermeland Mouzinga, Carola Horn, Isabelle Suarez, Ferdinand Heyn, Diane Alexia Fila, Hubert Banguissa, Fabien Roch Niama, Donatien Moukassa, Eva Heger, Francine Ntoumi, Clara Lehmann   +16 more
wiley   +1 more source

Efficacy and safety of switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed Asian adults living with HIV: A pooled analysis from three international phase III randomized trials

HIV Medicine, 2022
Data on switching to bictegravir, emtricitabine, and tenofovir alafenamide (B/F/TAF) in virologically suppressed Asian people living with HIV are limited.
A. Avihingsanon, P. Chetchotisakd, S. Kiertiburanakul, W. Ratanasuwan, K. Siripassorn, K. Supparatpinyo, Hal Martin, Hui Wang, Tak-Lam Wong, Hsiu-Yin Wang   +9 more
semanticscholar   +1 more source

Prior PrEP use and discontinuation in individuals newly diagnosed with HIV

HIV Medicine, EarlyView.
Abstract Background In settings with high uptake of HIV pre‐exposure prophylaxis (PrEP), an increasing proportion of individuals newly diagnosed with HIV report prior PrEP exposure. Understanding patterns of PrEP use, discontinuation and adherence in such settings is essential to inform future HIV prevention strategies.
Rohan Saini, Sarah Fidler, Marta Boffito, Vicky Tittle, Nicolo Girometti, Gary Whitlock, on behalf of the Dean Street Collaborative Group, Keerti Gedela, Franki Lander, Alan McOwan, Diarmuid Nugent, Sheel Patel, Sashini Payagala, Tara Suchak, Vicky Tittle, Gary Whitlock   +15 more
wiley   +1 more source

Effectiveness of rosuvastatin plus colchicine, emtricitabine/tenofovir and combinations thereof in hospitalized patients with COVID-19: a pragmatic, open-label randomized trial

EClinicalMedicine, 2021
Summary Background The use of rosuvastatin plus colchicine and emtricitabine/tenofovir in hospitalized patients with SARS-CoV-2 disease (COVID-19) has not been assessed.
MD MSc H.G. Gait an-Duarte, MD PhD C. Alvarez-Moreno, MSc C.J. Rinc on-Rodríguez, MD N. Yomayusa-Gonz alez, MD J.A. Cort es, MD PhD J.C. Villar, MD J.S. Bravo-Ojeda, MD MSc A. García-Pe na, PhD W. Adarme-Jaimes, PhD V.A. Rodríguez-Romero, MSc S.L. Villate-Soto, MD PhD G. Buitrago, MD J. Chac on-Sarmiento, MSc M. Macias-Quintero, MSc C.P. Vaca, MD PhD C. G omez-Restrepo, N. Rodríguez-Malag   +16 more
semanticscholar   +1 more source

Acute myocardial infarction associated with abacavir and tenofovir based antiretroviral drug combinations in the United States

AIDS Research and Therapy, 2021
Introduction Although individual antiretroviral drugs have been shown to be associated with elevated cardiovascular disease (CVD) risk, data are limited on the role of antiretroviral drug combinations.
Kunchok Dorjee, Manisha Desai, Tsering Choden, Sanjiv M. Baxi, Alan E. Hubbard, Arthur L. Reingold   +5 more
doaj   +1 more source

Dolutegravir population pharmacokinetics in racially, sex‐ and age‐diverse and antiretroviral therapy‐experienced adults with HIV in the United States

HIV Medicine, EarlyView.
Abstract Objectives Dolutegravir (DTG) has been associated with weight gain in women with HIV, Black people with HIV and people with HIV60 years. This study aimed to characterise DTG population pharmacokinetics (PopPK) in a diverse population including these sub‐populations.
Adrian Khoei, Andrew Edmonds, Yen Chang, Catalina Ramirez, Mackenzie Vogan, Amanda Poliseno, Steven Wolinsky, Ken Ho, Todd T. Brown, Joseph B. Margolick, Jacquett Batson, Jennifer Hoffmann, Mark A. Marzinke, Mirjam‐Colette Kempf, Maria L. Alcaide, Joffi Effoe, Cecile D. Lahiri, Igho Ofotokun, Anandi N. Sheth, Stephen Gange, Audrey L. French, Bani Tamraz, Bradley E. Aouizerat, Phyllis C. Tien, Seble G. Kassaye, Jack DeHovitz, Kathryn Anastos, Kara W. Chew, Michelle Floris‐Moore, Julie B. Dumond   +29 more
wiley   +1 more source

Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Black Americans With HIV-1: A Randomized Phase 3b, Multicenter, Open-Label Study

Journal of Acquired Immune Deficiency Syndromes, 2021
Supplemental Digital Content is Available in the Text. Background: With the highest rates of HIV/AIDS in the United States, Black Americans are still underrepresented in HIV medical research.
D. Hagins, Princy N. Kumar, M. Saag, A. Wurapa, I. Brar, D. Berger, O. Osiyemi, Corrilynn O Hileman, M. Ramgopal, Cheryl Mcdonald, C. Blair, Kristen Andreatta, Sean E. Collins, D. Brainard, Hal Martin   +14 more
semanticscholar   +1 more source

Characteristics and management of low‐level viraemia in people living with HIV in a resource‐limited setting: A multicentre retrospective study in Greece

HIV Medicine, EarlyView.
Abstract Objectives Low‐level viraemia (LLV) persists in some people living with HIV despite antiretroviral therapy, raising concerns about virologic failure. We assessed the characteristics, management and outcomes of LLV in Greece, where next‐generation sequencing, therapeutic drug monitoring and electronic adherence monitoring are unavailable ...
Lydia Leonidou, Giota Lourida, Konstantinos Protopapas, Charalampos D. Moschopoulos, Dimitrios Zoulas, Charisis Totsikas, Dimitrios Basoulis, Elpida Mastrogianni, Apostolos Beloukas, Maria Lagadinou, Markos Marangos, Vasileios Papastamopoulos, Antonios Papadopoulos, Mina Psichogiou   +13 more
wiley   +1 more source